The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Type 2 diabetes (T2D) patients with CKD will be eligible for the approval. The new indication makes Ozempic the first glucagon-like peptide-1 receptor agonist (GLP-1RA) available for people with T2D ...

Trading under the symbol ‘MTSR’, the company said it plans to use the funds to advance its glucagon-like peptide-1 receptor agonist (GLP-1RA) asset MET-097i through a Phase III trial. MET-097i ...

Ascletis Pharma has reported positive topline outcomes from its US Phase Ia single ascending dose (SAD) study of the oral tablet, ASC30, in obese individuals. The study, which involved 40 obese ...

Injecting old mice with an RNA molecule seems to reverse some signs of ageing — helping them to live longer, regrow hair and maintain their physical and mental abilities. Ageing studies in five ...